Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 100.02% and Operating profit at 7.57% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -9.12
2
Flat results in Jun 24
3
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
132.5%
0%
132.5%
6 Months
304.99%
0%
304.99%
1 Year
491.49%
0%
491.49%
2 Years
283.83%
0%
283.83%
3 Years
395.17%
0%
395.17%
4 Years
171.03%
0%
171.03%
5 Years
43.09%
0%
43.09%
Nanobiotix SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
100.02%
EBIT Growth (5y)
7.57%
EBIT to Interest (avg)
-9.12
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
0.09
Tax Ratio
11.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-15.93
EV to EBIT
-36.81
EV to EBITDA
-38.96
EV to Capital Employed
-15.47
EV to Sales
28.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
30.10
0.00
Operating Profit (PBDIT) excl Other Income
-28.90
-49.00
41.02%
Interest
8.00
5.80
37.93%
Exceptional Items
-4.90
-1.00
-390.00%
Consolidate Net Profit
-39.70
-57.00
30.35%
Operating Profit Margin (Excl OI)
-1,010.90%
0.00%
-101.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 30.35% vs -21.28% in Dec 2022
About Nanobiotix SA 
Nanobiotix SA
Pharmaceuticals & Biotechnology
Nanobiotix SA is a France-based oncology-focused nanomedicine company. The Company is engaged in developing nanoparticle technology. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The Company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Company Coordinates 
Company Details
60 rue de Wattignies , PARIS None : 75012
Registrar Details






